BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019;68:1688-700. [PMID: 31127023 DOI: 10.1136/gutjnl-2018-317977] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 18.3] [Reference Citation Analysis]
Number Citing Articles
1 Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Caër C, Wick MJ. Human Intestinal Mononuclear Phagocytes in Health and Inflammatory Bowel Disease. Front Immunol 2020;11:410. [PMID: 32256490 DOI: 10.3389/fimmu.2020.00410] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
3 Ye C, Zhu S, Yuan J. Construction of ceRNA Network to Reveal Potential Biomarkers in Crohn's Disease and Validation in a TNBS Induced Mice Model. J Inflamm Res 2021;14:6447-59. [PMID: 34880646 DOI: 10.2147/JIR.S338053] [Reference Citation Analysis]
4 Paap EM, Müller TM, Sommer K, Neurath MF, Zundler S. Total Recall: Intestinal TRM Cells in Health and Disease. Front Immunol 2020;11:623072. [PMID: 33542725 DOI: 10.3389/fimmu.2020.623072] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Alhouayek M, Ameraoui H, Muccioli GG. Bioactive lipids in inflammatory bowel diseases - From pathophysiological alterations to therapeutic opportunities. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158854. [PMID: 33157277 DOI: 10.1016/j.bbalip.2020.158854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Roosenboom B, Lochem EGV, Meijer J, Smids C, Nierkens S, Brand EC, Erp LWV, Kemperman LGJM, Groenen MJM, Horje CSHT, Wahab PJ. Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells 2020;9:E891. [PMID: 32268498 DOI: 10.3390/cells9040891] [Reference Citation Analysis]
7 Li H, Zhang Y, Liu M, Fan C, Feng C, Lu Q, Xiang C, Lu H, Yang X, Wu B, Zou D, Tang W. Targeting PDE4 as a promising therapeutic strategy in chronic ulcerative colitis through modulating mucosal homeostasis. Acta Pharm Sin B 2022;12:228-45. [PMID: 35127382 DOI: 10.1016/j.apsb.2021.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31281-7. [PMID: 32931960 DOI: 10.1016/j.cgh.2020.09.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Meneghini M, Bestard O, Grinyo JM. Immunosuppressive drugs modes of action. Best Pract Res Clin Gastroenterol 2021;54-55:101757. [PMID: 34874841 DOI: 10.1016/j.bpg.2021.101757] [Reference Citation Analysis]
10 Aasly JO. Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort. Front Neurosci 2021;15:634666. [PMID: 33584195 DOI: 10.3389/fnins.2021.634666] [Reference Citation Analysis]
11 Zhang W, Tyrrell H, Ding HT, Pulley J, Boruvka A, Erickson R, Abouhossein M, Ravanello R, Tang MT. Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers. Adv Ther 2021;38:2418-34. [PMID: 33778929 DOI: 10.1007/s12325-021-01661-6] [Reference Citation Analysis]
12 Lv Q, Xing Y, Liu J, Dong D, Liu Y, Qiao H, Zhang Y, Hu L. Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation. Acta Pharm Sin B 2021;11:2880-99. [PMID: 34589402 DOI: 10.1016/j.apsb.2021.03.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
13 Binienda A, Fichna J, Salaga M. Recent advances in inflammatory bowel disease therapy. European Journal of Pharmaceutical Sciences 2020;155:105550. [DOI: 10.1016/j.ejps.2020.105550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Liu W, Dong Z, Liu K, Lu Y, Wu W, Qi J, Chen Z. Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease. Int J Pharm 2021;600:120461. [PMID: 33711470 DOI: 10.1016/j.ijpharm.2021.120461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sandborn WJ, Mattheakis LC, Modi NB, Pugatch D, Bressler B, Lee S, Bhandari R, Kanwar B, Shames R, D'Haens G, Schreiber S, Danese S, Feagan B, Pai RK, Liu DY, Gupta S. PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. Gastroenterology 2021:S0016-5085(21)03463-6. [PMID: 34474038 DOI: 10.1053/j.gastro.2021.08.045] [Reference Citation Analysis]
16 Xue G, Hua L, Liu D, Zhong M, Chen Y, Zhou B, Xie Y, Li J. Tim-4 expressing monocytes as a novel indicator to assess disease activity and severity of ulcerative colitis. Life Sci 2021;269:119077. [PMID: 33465392 DOI: 10.1016/j.lfs.2021.119077] [Reference Citation Analysis]
17 Vitali F, Simon D, Neurath MF, Schett G, Zundler S. Vedolizumab-associated enthesitis: correlation or causality? Rheumatology (Oxford) 2021;60:5491-2. [PMID: 33930133 DOI: 10.1093/rheumatology/keab396] [Reference Citation Analysis]
18 Zundler S. Zellmigration als therapeutischer Zielprozess. Drug Res (Stuttg) 2021;71:S26-7. [PMID: 34788886 DOI: 10.1055/a-1606-5983] [Reference Citation Analysis]
19 Monteleone G, Franzè E, Troncone E, Maresca C, Marafini I. Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut. Front Immunol 2022;13:873332. [DOI: 10.3389/fimmu.2022.873332] [Reference Citation Analysis]
20 Tyrrell H, Ravanello R, Pulley J, Tang MT, Zhang W, Abouhossein M, Tole S. An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers. Adv Ther 2021;38:2406-17. [PMID: 33778928 DOI: 10.1007/s12325-021-01651-8] [Reference Citation Analysis]
21 Marafini I, Troncone E, Rocchetti I, Monteleone G. Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2020;11:585732. [PMID: 33551798 DOI: 10.3389/fphar.2020.585732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mühl L, Becker E, Müller TM, Atreya R, Atreya I, Neurath MF, Zundler S. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol 2021;21:33. [PMID: 33482730 DOI: 10.1186/s12876-021-01604-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Liu Y, Fang H, Liu H, Cheng H, Pan L, Hu M, Li X. Goji berry juice fermented by probiotics attenuates dextran sodium sulfate-induced ulcerative colitis in mice. Journal of Functional Foods 2021;83:104491. [DOI: 10.1016/j.jff.2021.104491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
24 Chen H, Chen C, Yuan X, Xu W, Yang MQ, Li Q, Shen Z, Yin L. Identification of Immune Cell Landscape and Construction of a Novel Diagnostic Nomogram for Crohn's Disease. Front Genet 2020;11:423. [PMID: 32425988 DOI: 10.3389/fgene.2020.00423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
25 Müller TM, Becker E, Wiendl M, Schulze LL, Voskens C, Völkl S, Kremer AE, Neurath MF, Zundler S. Circulating Adaptive Immune Cells Expressing the Gut Homing Marker α4β7 Integrin Are Decreased in COVID-19. Front Immunol 2021;12:639329. [PMID: 33959123 DOI: 10.3389/fimmu.2021.639329] [Reference Citation Analysis]
26 Cluny NL, Nyuyki KD, Almishri W, Griffin L, Lee BH, Hirota SA, Pittman QJ, Swain MG, Sharkey KA. Recruitment of α4β7 monocytes and neutrophils to the brain in experimental colitis is associated with elevated cytokines and anxiety-like behavior. J Neuroinflammation 2022;19:73. [PMID: 35379260 DOI: 10.1186/s12974-022-02431-z] [Reference Citation Analysis]
27 Zundler S, Tauschek V, Neurath MF. Immune Cell Circuits in Mucosal Wound Healing: Clinical Implications. Visc Med 2020;36:129-36. [PMID: 32355670 DOI: 10.1159/000506846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Picardo S, Panaccione R. Anti-MADCAM therapy for ulcerative colitis. Expert Opin Biol Ther 2020;20:437-42. [PMID: 31709847 DOI: 10.1080/14712598.2020.1691520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 D'Amico F, Danese S, Peyrin-Biroulet L. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? Expert Opin Biol Ther 2020;20:353-61. [PMID: 31951748 DOI: 10.1080/14712598.2020.1717465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Sommer K, Wiendl M, Müller TM, Heidbreder K, Voskens C, Neurath MF, Zundler S. Intestinal Mucosal Wound Healing and Barrier Integrity in IBD-Crosstalk and Trafficking of Cellular Players. Front Med (Lausanne) 2021;8:643973. [PMID: 33834033 DOI: 10.3389/fmed.2021.643973] [Reference Citation Analysis]
31 Ortega MA, Fraile-martinez O, Garcia-montero C, Alvarez-mon MA, Gomez-lahoz AM, Albillos A, Lahera G, Quintero J, Monserrat J, Guijarro LG, Alvarez-mon M. An Updated View of the Importance of Vesicular Trafficking and Transport and Their Role in Immune-Mediated Diseases: Potential Therapeutic Interventions. Membranes 2022;12:552. [DOI: 10.3390/membranes12060552] [Reference Citation Analysis]
32 Chen H, Chen L, Wang X, Ge X, Sun L, Wang Z, Xu X, Song Y, Chen J, Deng Q, Xie H, Chen T, Chen Y, Ding K, Wu J, Wang J. Transgenic overexpression of ITGB6 in intestinal epithelial cells exacerbates dextran sulfate sodium-induced colitis in mice. J Cell Mol Med 2021;25:2679-90. [PMID: 33491282 DOI: 10.1111/jcmm.16297] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Yang B, Zhang G, Elias M, Zhu Y, Wang J. The role of cytokine and immune responses in intestinal fibrosis. J Dig Dis 2020;21:308-14. [PMID: 32410365 DOI: 10.1111/1751-2980.12879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Marafini I, Monteleone G. Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases. Biologics 2020;14:47-51. [PMID: 32606588 DOI: 10.2147/BTT.S257638] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Zhu M, Mu JX, Jiang MS, Mukherjee A, Zeng Z, Chen YD, Yang XL, Zhang H. Chinese research into ulcerative colitis from 1978 to 2017: A bibliometric analysis. World J Meta-Anal 2020; 8(2): 163-172 [DOI: 10.13105/wjma.v8.i2.163] [Reference Citation Analysis]
36 Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol 2021;18:544-58. [PMID: 33712743 DOI: 10.1038/s41575-021-00424-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Melde M, Müller TM, Schneider I, Geppert CI, Mühl L, Besendorf L, Allner C, Becker E, Atreya I, Vitali F, Atreya R, Neurath MF, Zundler S. α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis. Therap Adv Gastroenterol 2021;14:17562848211054707. [PMID: 34868349 DOI: 10.1177/17562848211054707] [Reference Citation Analysis]
38 Gamliel A, Werner L, Pinsker M, Salamon N, Weiss B, Shouval DS. Circulating α4β7+ Memory T Cells in Pediatric IBD Patients Express a Polyclonal T Cell Receptor Repertoire. Clin Exp Gastroenterol 2020;13:439-47. [PMID: 33061522 DOI: 10.2147/CEG.S271565] [Reference Citation Analysis]
39 Scarozza P, Marafini I, Laudisi F, Troncone E, Schmitt H, Lenti MV, Costa S, Rocchetti I, De Cristofaro E, Salvatori S, Frezzati L, Di Sabatino A, Atreya R, Neurath MF, Calabrese E, Monteleone G. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. J Clin Med 2020;9:E385. [PMID: 32024071 DOI: 10.3390/jcm9020385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zundler S, Wiendl M, Neurath MF. Anti-trafficking agents in the treatment of inflammatory bowel disease. Current Opinion in Gastroenterology 2019;35:499-506. [DOI: 10.1097/mog.0000000000000579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Fournier AP, Martinez de Lizarrondo S, Rateau A, Gerard-brisou A, Waldner MJ, Neurath MF, Vivien D, Docagne F, Gauberti M. Ultrasensitive molecular imaging of intestinal mucosal inflammation using leukocyte-mimicking particles targeted to MAdCAM-1 in mice. Sci Transl Med 2020;12:eaaz4047. [DOI: 10.1126/scitranslmed.aaz4047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
43 Lu PD, Yuan MC, Quan XP, Chen JF, Zhao YH. Preclinical studies of licorice in ulcerative colitis: A systematic review with meta-analysis and network pharmacology. J Ethnopharmacol 2022;:115444. [PMID: 35671864 DOI: 10.1016/j.jep.2022.115444] [Reference Citation Analysis]
44 Choi SH, Barker EC, Gerber KJ, Letterio JJ, Kim BG. Loss of p27Kip1 leads to expansion of CD4+ effector memory T cells and accelerates colitis-associated colon cancer in mice with a T cell lineage restricted deletion of Smad4. Oncoimmunology 2020;9:1847832. [PMID: 33329939 DOI: 10.1080/2162402X.2020.1847832] [Reference Citation Analysis]
45 Becker E, Dedden M, Gall C, Wiendl M, Ekici AB, Schulz-Kuhnt A, Schweda A, Voskens C, Hegazy A, Vitali F, Atreya R, Müller TM, Atreya I, Neurath MF, Zundler S. Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. Gut 2021:gutjnl-2021-324868. [PMID: 34462337 DOI: 10.1136/gutjnl-2021-324868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Lutter L, Roosenboom B, Brand EC, Ter Linde JJ, Oldenburg B, van Lochem EG, Horje Talabur Horjus CS, van Wijk F. Homeostatic Function and Inflammatory Activation of Ileal CD8+ Tissue-Resident T Cells Is Dependent on Mucosal Location. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00137-5. [PMID: 34224909 DOI: 10.1016/j.jcmgh.2021.06.022] [Reference Citation Analysis]
47 Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. BioDrugs 2021;35:473-503. [PMID: 34613592 DOI: 10.1007/s40259-021-00496-5] [Reference Citation Analysis]
48 Allner C, Melde M, Becker E, Fuchs F, Mühl L, Klenske E, Müller L, Morgenstern N, Fietkau K, Hirschmann S, Atreya R, Atreya I, Neurath MF, Zundler S. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterol 2020;20:103. [PMID: 32293299 DOI: 10.1186/s12876-020-01253-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]